Update on rimonabant - A selective cannabinoid CB1 antagonist [1]

Annals of Pharmacotherapy

Volumn 40, Issue 5, 2006, Pages 994-

  Boyd, Steven T ^a   Fremming, Brad Allen ^b  

^a XAVIER UNIVERSITY OF LOUISIANA   (United States)

^b Offutt Air Force Base   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR ANTAGONIST; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; RECEPTOR BLOCKING AGENT; RIMONABANT; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANXIETY DISORDER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DEPRESSION; DRUG EFFECT; DRUG EFFICACY; HUMAN; LETTER; OBESITY; OUTCOME ASSESSMENT; OUTCOMES RESEARCH; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION;

CARDIOVASCULAR DISEASES; DYSLIPIDEMIAS; HUMANS; OBESITY; PIPERIDINES; PYRAZOLES; RANDOMIZED CONTROLLED TRIALS; RECEPTOR, CANNABINOID, CB1; RISK FACTORS;

EID: 33646791152     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1G713     Document Type: Letter

References (3)

1. Boyd ST, Fremming BA. Rimonabant-a selective CB1 antagonist. Ann Pharmacother 2005;39:684-90. Epub 8 Mar 2005. DOI 10.1345/aph.1E499
2. VanGaal L. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patient: 1 year experience from the RIO-Europe study. Lancet 2005;365:1389.
3. Despres J, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 353;20:2121-34.